CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

Abroad (travel likely)RecruitingPHASE1

Conditions

SLE - Systemic Lupus Erythematosus · SSc-Systemic Sclerosis · IIM- Idiopathic Inflammatory Myopathies · ANCA Associated Vasculitis (AAV) · Connective Tissue Disease-Associated Thrombocytopenia · SLE-ITP

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Institute of Hematology & Blood Diseases Hospital, Tianjin, China

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases

Myocarditis · ANCA Associated Vasculitis · Pericarditis

Abroad (travel likely)Recruiting

Paris, France

Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

Autoimmune Diseases · Systemic Lupus Erythematosus · Systemic Sclerosis

Abroad (travel likely)RecruitingEARLY_PHASE1

Shanghai, China

CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

SLE · Systemic Lupus Erythematosus (SLE) · CAR T Cell

Abroad (travel likely)RecruitingPHASE1, PHASE2

Philadelphia, United States

Rheumatology Patient Registry and Biorepository

Rheumatic Diseases · Adult Onset Still Disease · Ankylosing Spondylitis

Abroad (travel likely)Recruiting

New Haven, United States